Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.

Vitale M, Cantoni C, Della Chiesa M, Ferlazzo G, Carlomagno S, Pende D, Falco M, Pessino A, Muccio L, De Maria A, Marcenaro E, Moretta L, Sivori S.

Front Immunol. 2019 Jun 19;10:1415. doi: 10.3389/fimmu.2019.01415. eCollection 2019. Review.

2.

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.

Pesce S, Greppi M, Grossi F, Del Zotto G, Moretta L, Sivori S, Genova C, Marcenaro E.

Front Immunol. 2019 Jun 4;10:1242. doi: 10.3389/fimmu.2019.01242. eCollection 2019. Review.

3.

NK cells to cure cancer.

Di Vito C, Mikulak J, Zaghi E, Pesce S, Marcenaro E, Mavilio D.

Semin Immunol. 2019 May 10:101272. doi: 10.1016/j.smim.2019.03.004. [Epub ahead of print] Review.

PMID:
31085114
4.

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.

Cristiani CM, Turdo A, Ventura V, Apuzzo T, Capone M, Madonna G, Mallardo D, Garofalo C, Giovannone ED, Grimaldi AM, Tallerico R, Marcenaro E, Pesce S, Del Zotto G, Agosti V, Costanzo FS, Gulletta E, Rizzo A, Moretta A, Karre K, Ascierto PA, Todaro M, Carbone E.

Cancer Immunol Res. 2019 May;7(5):841-852. doi: 10.1158/2326-6066.CIR-18-0651. Epub 2019 Apr 2.

PMID:
30940644
5.

Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.

Greppi M, Tabellini G, Patrizi O, Candiani S, Decensi A, Parolini S, Sivori S, Pesce S, Paleari L, Marcenaro E.

Int J Mol Sci. 2019 Feb 19;20(4). pii: E890. doi: 10.3390/ijms20040890. Review.

6.

PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua.

Vacca P, Pesce S, Greppi M, Fulcheri E, Munari E, Olive D, Mingari MC, Moretta A, Moretta L, Marcenaro E.

Mucosal Immunol. 2019 May;12(3):624-631. doi: 10.1038/s41385-019-0141-9. Epub 2019 Feb 12.

PMID:
30755717
7.

PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression.

Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F, Munari E, Pesce S, Marcenaro E, Moretta A, Vacca P, Moretta L.

Oncoimmunology. 2018 Dec 25;8(3):1557030. doi: 10.1080/2162402X.2018.1557030. eCollection 2019.

8.

Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.

Zaghi E, Calvi M, Marcenaro E, Mavilio D, Di Vito C.

J Leukoc Biol. 2019 Jun;105(6):1243-1251. doi: 10.1002/JLB.MR0718-300R. Epub 2019 Jan 15. Review.

PMID:
30645023
9.

New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression.

Pesce S, Squillario M, Greppi M, Loiacono F, Moretta L, Moretta A, Sivori S, Castagnola P, Barla A, Candiani S, Marcenaro E.

Front Immunol. 2018 Oct 15;9:2360. doi: 10.3389/fimmu.2018.02360. eCollection 2018.

10.

The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation.

Roberto A, Di Vito C, Zaghi E, Mazza EMC, Capucetti A, Calvi M, Tentorio P, Zanon V, Sarina B, Mariotti J, Bramanti S, Tenedini E, Tagliafico E, Bicciato S, Santoro A, Roederer M, Marcenaro E, Castagna L, Lugli E, Mavilio D.

Haematologica. 2018 Aug;103(8):1390-1402. doi: 10.3324/haematol.2017.186619. Epub 2018 Apr 26.

11.

Editorial: NK Cell Subsets in Health and Disease: New Developments.

Marcenaro E, Notarangelo LD, Orange JS, Vivier E.

Front Immunol. 2017 Oct 18;8:1363. doi: 10.3389/fimmu.2017.01363. eCollection 2017. No abstract available.

12.

Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content.

Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J, Booth C, Buchbinder D, Burns SO, Chatila TA, Chou J, Daza-Cajigal V, Ott de Bruin LM, de la Morena MT, Di Matteo G, Finocchi A, Geha R, Goyal RK, Hayward A, Holland S, Huang CH, Kanariou MG, King A, Kaplan B, Kleva A, Kuijpers TW, Lee BW, Lougaris V, Massaad M, Meyts I, Morsheimer M, Neven B, Pai SY, Parvaneh N, Plebani A, Prockop S, Reisli I, Soh JY, Somech R, Torgerson TR, Kim YJ, Walter JE, Gennery AR, Keles S, Manis JP, Marcenaro E, Moretta A, Parolini S, Notarangelo LD.

Front Immunol. 2017 Oct 10;8:1244. doi: 10.3389/fimmu.2017.01244. eCollection 2017.

13.

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C.

Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2.

14.

Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content.

Dobbs K, Tabellini G, Calzoni E, Patrizi O, Martinez P, Giliani SC, Moratto D, Al-Herz W, Cancrini C, Cowan M, Bleesing J, Booth C, Buchbinder D, Burns SO, Chatila TA, Chou J, Daza-Cajigal V, Ott de Bruin LM, de la Morena M, Di Matteo G, Finocchi A, Geha R, Goyal RK, Hayward A, Holland S, Huang CH, Kanariou MG, King A, Kaplan B, Kleva A, Kuijpers TW, Lee BW, Lougaris V, Massaad M, Meyts I, Morsheimer M, Neven B, Pai SY, Parvaneh N, Plebani A, Prockop S, Reisli I, Soh JY, Somech R, Torgerson TR, Kim YJ, Walter JE, Gennery AR, Keles S, Manis JP, Marcenaro E, Moretta A, Parolini S, Notarangelo LD.

Front Immunol. 2017 Jul 17;8:798. doi: 10.3389/fimmu.2017.00798. eCollection 2017. Erratum in: Front Immunol. 2017 Oct 10;8:1244.

15.

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands.

Pesce S, Thoren FB, Cantoni C, Prato C, Moretta L, Moretta A, Marcenaro E.

Front Immunol. 2017 Apr 28;8:510. doi: 10.3389/fimmu.2017.00510. eCollection 2017.

16.

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.

Gross CC, Schulte-Mecklenbeck A, Wiendl H, Marcenaro E, Kerlero de Rosbo N, Uccelli A, Laroni A.

Front Immunol. 2016 Dec 19;7:606. doi: 10.3389/fimmu.2016.00606. eCollection 2016. Review.

17.

Markers and function of human NK cells in normal and pathological conditions.

Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L.

Cytometry B Clin Cytom. 2017 Mar;92(2):100-114. doi: 10.1002/cyto.b.21508. Epub 2017 Feb 12. Review.

18.

Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor.

Pesce S, Moretta L, Moretta A, Marcenaro E.

Front Immunol. 2016 Oct 7;7:414. eCollection 2016. Review.

19.

Features of Memory-Like and PD-1(+) Human NK Cell Subsets.

Della Chiesa M, Pesce S, Muccio L, Carlomagno S, Sivori S, Moretta A, Marcenaro E.

Front Immunol. 2016 Sep 14;7:351. doi: 10.3389/fimmu.2016.00351. eCollection 2016. Review.

20.

Cognate HLA absence in trans diminishes human NK cell education.

Landtwing V, Raykova A, Pezzino G, Béziat V, Marcenaro E, Graf C, Moretta A, Capaul R, Zbinden A, Ferlazzo G, Malmberg KJ, Chijioke O, Münz C.

J Clin Invest. 2016 Oct 3;126(10):3772-3782. doi: 10.1172/JCI86923. Epub 2016 Aug 29.

21.

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization.

Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E.

J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3. doi: 10.1016/j.jaci.2016.04.025. Epub 2016 May 27.

PMID:
27372564
22.

Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.

Laroni A, Armentani E, Kerlero de Rosbo N, Ivaldi F, Marcenaro E, Sivori S, Gandhi R, Weiner HL, Moretta A, Mancardi GL, Uccelli A.

J Autoimmun. 2016 Aug;72:8-18. doi: 10.1016/j.jaut.2016.04.003. Epub 2016 May 4.

23.

Priming of Human Resting NK Cells by Autologous M1 Macrophages via the Engagement of IL-1β, IFN-β, and IL-15 Pathways.

Mattiola I, Pesant M, Tentorio PF, Molgora M, Marcenaro E, Lugli E, Locati M, Mavilio D.

J Immunol. 2015 Sep 15;195(6):2818-28. doi: 10.4049/jimmunol.1500325. Epub 2015 Aug 14.

24.

B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape.

Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini S, Marcenaro E.

Oncoimmunology. 2015 Jan 22;4(4):e1001224. eCollection 2015 Apr.

25.

TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses.

Riise RE, Bernson E, Aurelius J, Martner A, Pesce S, Della Chiesa M, Marcenaro E, Bylund J, Hellstrand K, Moretta L, Moretta A, Thorén FB.

J Immunol. 2015 Aug 1;195(3):1121-8. doi: 10.4049/jimmunol.1500709. Epub 2015 Jun 17.

26.

Uptake of CCR7 by KIR2DS4⁺ NK cells is induced upon recognition of certain HLA-C alleles.

Pesce S, Carlomagno S, Moretta A, Sivori S, Marcenaro E.

J Immunol Res. 2015;2015:754373. doi: 10.1155/2015/754373. Epub 2015 Apr 16.

27.

Role of the 2B4 Receptor in CD8+ T-Cell-Dependent Immune Control of Epstein-Barr Virus Infection in Mice With Reconstituted Human Immune System Components.

Chijioke O, Marcenaro E, Moretta A, Capaul R, Münz C.

J Infect Dis. 2015 Sep 1;212(5):803-7. doi: 10.1093/infdis/jiv114. Epub 2015 Feb 26.

28.

NK Cell Subset Redistribution during the Course of Viral Infections.

Lugli E, Marcenaro E, Mavilio D.

Front Immunol. 2014 Aug 14;5:390. doi: 10.3389/fimmu.2014.00390. eCollection 2014. Review.

29.

TLR/NCR/KIR: Which One to Use and When?

Sivori S, Carlomagno S, Pesce S, Moretta A, Vitale M, Marcenaro E.

Front Immunol. 2014 Mar 19;5:105. doi: 10.3389/fimmu.2014.00105. eCollection 2014. Review.

30.

Human NK cell response to pathogens.

Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A.

Semin Immunol. 2014 Apr;26(2):152-60. doi: 10.1016/j.smim.2014.02.001. Epub 2014 Feb 28. Review.

PMID:
24582551
31.

Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis.

Tabellini G, Benassi M, Marcenaro E, Coltrini D, Patrizi O, Ricotta D, Rampinelli F, Moretta A, Parolini S.

Case Rep Oncol. 2014 Jan 24;7(1):70-8. doi: 10.1159/000357802. eCollection 2014 Jan.

32.

Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection.

Chijioke O, Müller A, Feederle R, Barros MH, Krieg C, Emmel V, Marcenaro E, Leung CS, Antsiferova O, Landtwing V, Bossart W, Moretta A, Hassan R, Boyman O, Niedobitek G, Delecluse HJ, Capaul R, Münz C.

Cell Rep. 2013 Dec 26;5(6):1489-98. doi: 10.1016/j.celrep.2013.11.041. Epub 2013 Dec 19. Erratum in: Cell Rep. 2015 Aug 4;12(5):901.

33.

KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts.

Marcenaro E, Pesce S, Sivori S, Carlomagno S, Moretta L, Moretta A.

Blood. 2013 Apr 25;121(17):3396-401. doi: 10.1182/blood-2012-09-458752. Epub 2013 Feb 28.

34.

Human NK Cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism.

Thorén FB, Riise RE, Ousbäck J, Della Chiesa M, Alsterholm M, Marcenaro E, Pesce S, Prato C, Cantoni C, Bylund J, Moretta L, Moretta A.

J Immunol. 2012 Feb 15;188(4):1668-74. doi: 10.4049/jimmunol.1102002. Epub 2012 Jan 9.

35.

NK/DC crosstalk in anti-viral response.

Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S.

Adv Exp Med Biol. 2012;946:295-308. doi: 10.1007/978-1-4614-0106-3_17. Review.

PMID:
21948375
36.

NK cells and their receptors during viral infections.

Marcenaro E, Carlomagno S, Pesce S, Della Chiesa M, Parolini S, Moretta A, Sivori S.

Immunotherapy. 2011 Sep;3(9):1075-86. doi: 10.2217/imt.11.99. Review.

PMID:
21913830
37.

Bridging innate NK cell functions with adaptive immunity.

Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S.

Adv Exp Med Biol. 2011;780:45-55. doi: 10.1007/978-1-4419-5632-3_5. Review.

PMID:
21842364
38.

Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.

Marcenaro E, Carlomagno S, Pesce S, Della Chiesa M, Moretta A, Sivori S.

J Leukoc Biol. 2011 Oct;90(4):661-7. doi: 10.1189/jlb.0311137. Epub 2011 Jul 26. Review.

PMID:
21791599
39.

Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation.

Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A.

Blood. 2011 Jan 20;117(3):764-71. doi: 10.1182/blood-2010-08-264085. Epub 2010 Oct 1. Review.

40.

Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection.

Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, Moretta A, Mavilio D.

AIDS. 2010 Jan 2;24(1):27-34. doi: 10.1097/QAD.0b013e3283328d1f.

PMID:
19910789
41.

Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction.

Marcenaro E, Cantoni C, Pesce S, Prato C, Pende D, Agaugué S, Moretta L, Moretta A.

Blood. 2009 Nov 5;114(19):4108-16. doi: 10.1182/blood-2009-05-222265. Epub 2009 Sep 11.

42.

The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia.

Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, Moretta A, Mavilio D.

Blood. 2009 Oct 29;114(18):3822-30. doi: 10.1182/blood-2009-06-226332. Epub 2009 Aug 26.

43.

The NK/DC complot.

Marcenaro E, Della Chiesa M, Pesce S, Agaugué S, Moretta A.

Adv Exp Med Biol. 2009;633:7-16. Review. No abstract available.

PMID:
19209677
44.

Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.

Fogli M, Mavilio D, Brunetta E, Varchetta S, Ata K, Roby G, Kovacs C, Follmann D, Pende D, Ward J, Barker E, Marcenaro E, Moretta A, Fauci AS.

PLoS Pathog. 2008 Jul 11;4(7):e1000101. doi: 10.1371/journal.ppat.1000101.

45.

Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC.

Marcenaro E, Ferranti B, Falco M, Moretta L, Moretta A.

Int Immunol. 2008 Sep;20(9):1155-67. doi: 10.1093/intimm/dxn073. Epub 2008 Jul 1.

PMID:
18596023
46.

Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells.

Agaugué S, Marcenaro E, Ferranti B, Moretta L, Moretta A.

Blood. 2008 Sep 1;112(5):1776-83. doi: 10.1182/blood-2008-02-135871. Epub 2008 Jun 25.

47.

In the thick of the fray: NK cells in inflamed tissues.

Marcenaro E, Della Chiesa M, Ferranti B, Moretta A.

Adv Exp Med Biol. 2007;598:12-9. Review. No abstract available.

PMID:
17892201
48.

NK cells at the interface between innate and adaptive immunity.

Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L.

Cell Death Differ. 2008 Feb;15(2):226-33. Epub 2007 Jun 1. Review.

49.

The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues.

Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M, Tabellini G, Moretta A, Sozzani S.

Blood. 2007 May 1;109(9):3625-32. Epub 2007 Jan 3.

50.

It's only innate immunity but I like it.

Marcenaro E, Della Chiesa M, Dondero A, Ferranti B, Moretta A.

Adv Exp Med Biol. 2007;590:89-101. Review. No abstract available.

PMID:
17191379

Supplemental Content

Loading ...
Support Center